Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

BASEL, Switzerland I 11, 2025 I Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, ...

Fresh off the heels of winning the bid to host the Eurovision Song Contest in 2025, after Swiss contestant and first openly nonbinary performer Nemo won the contest last year, Basel is ready for its ...

Real-time imaging shows that bacterial resilience to antibiotics is not caused by a few ‘persisters’, but is a ...

Roche, Novartis, Johnson & Johnson Innovative Medicine, Takeda, SHL Medical, Nestlé, Lindt & Sprüngli, Givaudan, Schneider Electric, Schindler, Endress+Hauser Flowtec, VAT Group and SFS Group. They ...

TD Cowen analyst Steve Scala reiterated a Hold rating on Novartis (NVS – Research Report) today and set a price target of $125.00. The ...

Novartis AG released its Annual Report for 2024, alongside its ‘Novartis in Society – Integrated Report 2024.’ This announcement underscores the company ...

BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company said it ...

Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance.

2025 in Basel, Switzerland. Taking over the successful series launched by the NCCR Chemical Biology, the meeting will continue its tradition of high scientific quality and bring together leading ...